# FreeStyle Libre

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/freestyle-libre
Canonical HTML page: https://getbiobrief.com/entity/freestyle-libre

## Recent coverage (1 stories)

### Cancer diagnostics push Abbott's 2026 EPS guidance to $5.45-$5.60
2026-07-17 03:45:55 · Sentiment: Bullish · Impact: 6/10 · Sources: 2

Abbott’s newly acquired oncology diagnostics from Exact Sciences—Cologuard and Oncotype DX—are offsetting COVID testing declines and powering a Q2 earnings beat. The company lifted its full-year 2026 adjusted EPS target, highlighting the value of high-margin, recurring precision testing businesses.
Full story: https://getbiobrief.com/story/abbott-cancer-diagnostics-2026-eps-forecast

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.